Benzinga's Small Cap Movers for Thursday November 29, 2012
Below are highlights from Benzinga's daily coverage of small cap securities making big moves:
Shares of THQ (NASDAQ: THQI), the Agoura Hills, CA developer and publisher of interactive entertainment softwarey, rose 38% Thursday on 6 times average volume.
There was chatroom and twitter chatter on Thursday, but no specific news.
THQ closed at $1.49 on Thursday.
Shares of Acura Pharmaceuticals (NASDAQ: ACUR), the Palatine, IL specialty pharmaceutical company, rose 37% Thursday on 23 times average volume.
Acura is about to launch Nexafed, a formulation that will impede the extraction of pseudoephedrine from the tablets to form methamphetamine. Nexafed's IMPEDE technology disrupts the conversion of pseudoephedrine into methamphetamine, while still providing nasal-congestion relief.
Nexafed is expected to launch by the end of the 2012.
Acura Pharmaceuticals closed at $1.95 on Thursday.
Shares of ZBB Energy (NYSE: ZBB), the Menomonee Falls, WI provider of electrical power management platforms for the renewable energy industry, rose 14% Thursday on average volume.
ZBB Energy announced Thursday a strategic supply agreement to provide controllers for Crosspoint Kinetics' second generation hybrid system.
Crosspoint Kinetics' second generation hybrid systems, initially serving the Class 4, 5 and 6 small to medium size bus markets in the United States, are valued for providing significantly greater fuel efficiency and reduced carbon emissions. Many fleets throughout North America presently have these systems operating in their equipment. The system is currently in limited production and being validated through additional testing and evaluation.
ZBB Energy closed at $0.24 on Thursday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.